KRAS variant allele frequency, but not mutation positivity, associates with survival of patients with pancreatic cancer.

doi:10.1111/cas.15398

Loading publication...

Noodle always counts identifier-free feature events for service operation. With your permission, Google Analytics can also estimate audience and engagement. Search text, publication identifiers, cookies, IP addresses and browser fingerprints are never included in Noodle's first-party event counters.

Privacy details

Community

Back to search

Article

KRAS variant allele frequency, but not mutation positivity, associates with survival of patients with pancreatic cancer.

Cancer science - 1 Sept 2022

Suzuki Tatsunori, Masugi Yohei, Inoue Yosuke, Hamada Tsuyoshi, Tanaka Mariko, Takamatsu Manabu, Arita Junichi, Kato Tomotaka, Kawaguchi Yoshikuni, Kunita Akiko, Nakai Yousuke, Nakano Yutaka, Ono Yoshihiro, Sasahira Naoki, Takeda Tsuyoshi, Tateishi Keisuke, Uemura Sho, Koike Kazuhiko, Ushiku Tetsuo, Takeuchi Kengo, Sakamoto Michiie, Hasegawa Kiyoshi, Kitago Minoru, Takahashi Yu, Fujishiro Mitsuhiro

Abstract excerpt

KRAS mutation is a major driver of pancreatic carcinogenesis and will likely be a therapeutic target. Due to lack of sensitive assays for clinical samples of pancreatic cancer with low cellularity, KRAS mutations and their prognostic association have not been fully examined in large populations. In a multi-institutional cohort of 1162 pancreatic cancer patients with formalin-fixed paraffin-embedded tumor samples,...

Read the complete abstract on PubMed

Topics

Share this publication in a Topic to start or enrich a Post.

Share to Biomarkers, Tumor

Methodology Data sources Editorial policy Privacy About Contact Helena Bioinformatics

Share to Cancer Genomics and Diagnostics

Share to Gene Frequency

Share to Mutation

Share to Pancreatic and Hepatic Oncology Research

Share to Pancreatic Neoplasms

Share to Prognosis

Share to Proto-Oncogene Proteins p21(ras)

Source

Open in PubMed Open full text

Identifiers

PMID: 35567350
DOI: 10.1111/cas.15398
PMCID: PMC9459293

Provenance

PubMed metadata and Literature Corpus relationships. Corpus snapshot updated 7 Sept 2026. Manifest publication-graph-cohort-2026-09-08.1.

Source receipt: pubmed, retrieved 7 Sept 2026.

Related research

Semantic proximity does not establish scientific evidence.

Research trail→

Click a neighbor to travelStep 1 · 12 closest

KRAS variant allele frequency, but not mutation positivity, associates with survival of patients with pancreatic cancer.PMID 35567350Read ↗

The Clinical Implications of KRAS Mutations and Variant Allele Frequencies in Pancreatic Ductal AdenocarcinomaSemantic proximity Read ↗

Identifying Actionable Alterations in KRAS Wild-Type Pancreatic Cancer.Semantic proximity Read ↗

KRAS mutations in blood circulating cell-free DNA: a pancreatic cancer case-control.Semantic proximity Read ↗

Variant Profiling of Candidate Genes in Pancreatic Ductal Adenocarcinoma.Semantic proximity Read ↗

KRAS, BRAF, and PIK3CA mutations, and patient prognosis in 126 pancreatic cancers: pyrosequencing technology and literature review.Semantic proximity Read ↗

Optimal Value of Mutant KRAS Circulating Tumor DNA for Predicting Prognosis and Monitoring in Patients with Pancreatic Adenocarcinoma: A Prospective Multicenter Cohort Study.Semantic proximity Read ↗

Prognostic Properties of KRAS Gene Mutation Subtypes in Resected Pancreatic Ductal Adenocarcinoma.Semantic proximity Read ↗

KRAS Mutant Allele Fraction in Circulating Cell-Free DNA Correlates With Clinical Stage in Pancreatic Cancer PatientsSemantic proximity Read ↗

Prognostic Implications of Multiplex Detection of KRAS Mutations in Cell-Free DNA from Patients with Pancreatic Ductal Adenocarcinoma.Semantic proximity Read ↗

Role of oncogenic KRAS in the diagnosis, prognosis and treatment of pancreatic cancer.Semantic proximity Read ↗

Prognostic Implications of Codon-Specific KRAS Mutations in Localized and Advanced Stages of Pancreatic Cancer.Semantic proximity Read ↗

Molecular Characterization of KRAS Wild-type Tumors in Patients with Pancreatic Adenocarcinoma.Semantic proximity Read ↗

⌁Select a neighboring publication to make it the new centre.